{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:46:40Z","timestamp":1787496400583,"version":"build-2736575974"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03114-4","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T06:11:35Z","timestamp":1748067095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database"],"prefix":"10.1038","volume":"15","author":[{"given":"Lele","family":"Ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"3114_CR1","doi-asserted-by":"publisher","first-page":"100221","DOI":"10.1016\/j.jpap.2023.100221","volume":"19","author":"AE Davis","year":"2024","unstructured":"Davis, A. E. et al. The phenomenon of phototoxicity and long-term risks of commonly prescribed and structurally diverse drugs. J. Photochem. Photobiol. 19, 100221 (2024).","journal-title":"J. Photochem. Photobiol"},{"key":"3114_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.25259\/IJSA_9_2024","volume":"3","author":"SB Pai","year":"2024","unstructured":"Pai, S. B. & Anchan, V. N. Phototoxicity and photoallergy\u2014A brief review on pathogenesis, recent advances, and approach to a patient with photosensitivity. IJSA 3, 28\u201335 (2024).","journal-title":"IJSA"},{"key":"3114_CR3","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40264-019-00806-5","volume":"42","author":"KM Blakely","year":"2019","unstructured":"Blakely, K. M., Drucker, A. M. & Rosen, C. F. Drug-Induced photosensitivity\u2014An update: Culprit drugs, prevention and management. Drug Saf. 42, 827\u2013847 (2019).","journal-title":"Drug Saf."},{"key":"3114_CR4","doi-asserted-by":"crossref","unstructured":"Khandpur, S., Porter, R. M., Boulton, S. J. & Anstey, A. Drug-induced photosensitivity: New insights into pathomechanisms and clinical variation through basic and applied science. Br. J. Dermatol. (2016).","DOI":"10.1111\/bjd.14935"},{"key":"3114_CR5","first-page":"19","volume":"19","author":"GA Hofmann","year":"2021","unstructured":"Hofmann, G. A. & Weber, B. Drug-induced photosensitivity: Culprit drugs, potential mechanisms and clinical consequences. J. Dtsch. Derma Gesell. 19, 19\u201329 (2021).","journal-title":"J. Dtsch. Derma Gesell"},{"key":"3114_CR6","unstructured":"Zuba, E. B., Koronowska, S., Osmola, A. & Jenerowicz, D. Drug-induced photosensitivity. Acta Dermatovenerologica Croatica."},{"key":"3114_CR7","first-page":"359","volume":"105","author":"S G\u00f3mez-Bernal","year":"2014","unstructured":"G\u00f3mez-Bernal, S. et al. Photosensitivity due to thiazides. Actas Dermo-Sifiliogr\u00e1ficas. (Engl. Ed.). 105, 359\u2013366 (2014).","journal-title":"(English Edition)"},{"key":"3114_CR8","doi-asserted-by":"publisher","unstructured":"Lugovi\u0107-Mihi\u0107, L. Drug-induced photosensitivity\u2014a continuing diagnostic challenge. acc 277\u2013283 (2017). https:\/\/doi.org\/10.20471\/acc.2017.56.02.11","DOI":"10.20471\/acc.2017.56.02.11"},{"key":"3114_CR9","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/phpp.12583","volume":"36","author":"A Alrashidi","year":"2020","unstructured":"Alrashidi, A. et al. Systemic drug photosensitivity\u2014culprits, impact and investigation in 122 patients. Photoderm. Photoimm. Photomed. 36, 441\u2013451 (2020).","journal-title":"Photoderm Photoimm Photomed."},{"key":"3114_CR10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.jaad.2018.06.061","volume":"79","author":"WB Kim","year":"2018","unstructured":"Kim, W. B. et al. Drug-induced phototoxicity: A systematic review. J. Am. Acad. Dermatol. 79, 1069\u20131075 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"3114_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796\u2013803 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"3114_CR12","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.2147\/CCID.S422928","volume":"16","author":"W Fei","year":"2023","unstructured":"Fei, W., Shen, J. & Cai, H. Causes of Drug-Induced severe cutaneous adverse reaction epidermal necrolysis (EN): An analysis using FDA adverse event reporting system (FAERS) database. CCID Volume. 16, 2249\u20132257 (2023).","journal-title":"CCID Volume"},{"key":"3114_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13, 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"3114_CR14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ajp.2010.09.002","volume":"3","author":"HT Huang","year":"2010","unstructured":"Huang, H. T., Chang, C. L. & Tzeng, D. S. Toxic epidermal necrolysis after sun-exposure probably due to lamotrigine and chlorpromazine. Asian J. Psychiatry. 3, 240\u2013242 (2010).","journal-title":"Asian J. Psychiatry"},{"key":"3114_CR15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","volume":"15","author":"J Larkin","year":"2014","unstructured":"Larkin, J. et al. Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 15, 436\u2013444 (2014).","journal-title":"Lancet Oncol."},{"key":"3114_CR16","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","volume":"28","author":"PB Chapman","year":"2017","unstructured":"Chapman, P. B. et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study. Ann. Oncol. 28, 2581\u20132587 (2017).","journal-title":"Ann. Oncol."},{"key":"3114_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman, J. A. et al. Survival in BRAF V600\u2013Mutant advanced melanoma treated with Vemurafenib. N. Engl. J. Med. 366, 707\u2013714 (2012).","journal-title":"N Engl. J. Med."},{"key":"3114_CR18","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1111\/bcp.13221","volume":"83","author":"F Borgia","year":"2017","unstructured":"Borgia, F. et al. Mucocutaneous toxicity during Simeprevir treatment for hepatitis C. A single institution, retrospective case series. Brit J. Clin. Pharm. 83, 1152\u20131154 (2017).","journal-title":"Brit J. Clin. Pharma"},{"key":"3114_CR19","doi-asserted-by":"publisher","first-page":"e01217","DOI":"10.1128\/AAC.01217-17","volume":"61","author":"S Bourgeois","year":"2017","unstructured":"Bourgeois, S. et al. Pharmacokinetic interactions between Simeprevir and Ledipasvir in Treatment-Naive hepatitis C virus genotype 1-Infected patients without cirrhosis treated with a Simeprevir-Sofosbuvir-Ledipasvir regimen. Antimicrob. Agents Chemother. 61, e01217\u2013e01217 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"3114_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jdcr.2016.03.007","volume":"2","author":"ZW Eyre","year":"2016","unstructured":"Eyre, Z. W., Secrest, A. M. & Woodcock, J. L. Photo-induced drug eruption in a patient on combination Simeprevir\/sofosbuvir for hepatitis C. JAAD Case Rep. 2, 224\u2013226 (2016).","journal-title":"JAAD Case Rep."},{"key":"3114_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns, M. et al. Simeprevir with pegylated interferon Alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384, 414\u2013426 (2014).","journal-title":"Lancet"},{"key":"3114_CR22","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1093\/cid\/cit600","volume":"57","author":"O Epaulard","year":"2013","unstructured":"Epaulard, O. et al. A multistep Voriconazole-Related phototoxic pathway May lead to skin carcinoma: Results from a French nationwide study. Clin. Infect. Dis. 57, e182\u2013e188 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"3114_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1365-2133.2012.11196.x","volume":"168","author":"AK Haylett","year":"2013","unstructured":"Haylett, A. K., Felton, S., Denning, D. W. & Rhodes, L. E. Voriconazole-induced photosensitivity: Photobiological assessment of a case series of 12 patients: Voriconazole-induced photosensitivity. Br. J. Dermatol. 168, 179\u2013185 (2013).","journal-title":"Br. J. Dermatol."},{"key":"3114_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jaad.2014.10.023","volume":"72","author":"J Sheu","year":"2015","unstructured":"Sheu, J., Hawryluk, E. B., Guo, D., London, W. B. & Huang, J. T. Voriconazole phototoxicity in children: A retrospective review. J. Am. Acad. Dermatol. 72, 314\u2013320 (2015).","journal-title":"J. Am. Acad. Dermatol."},{"key":"3114_CR25","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1128\/AAC.00068-13","volume":"57","author":"JGC Van Hasselt","year":"2013","unstructured":"Van Hasselt, J. G. C., Van Eijkelenburg, N. K. A., Huitema, A. D. R. & Schellens, J. H. M. Schouten-van Meeteren, A. Y. N. Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. Antimicrob. Agents Chemother. 57, 2878\u20132881 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"3114_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.51271\/JOPIC-0018","volume":"1","author":"E Akku\u015f","year":"2023","unstructured":"Akku\u015f, E., \u00c7elik, D., Yetkin, \u00d6. & Lakadamyal\u0131, H. Photodermatit developed with Pirfenidone treatment in patient diagnosed with IPF. JOPIC 1, 76\u201378 (2023).","journal-title":"JOPIC"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03114-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03114-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T06:11:37Z","timestamp":1748067097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03114-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3114"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03114-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18102"}}